MEN1 and Dravet syndrome: In this phase 1/2 single center open label clinical trial of a novel menin inhibitor, the agent was associated with clear evidence of DS which was manageable with no DS related mortality, The DS risk was further abated by implementing a lead-in step wise dosing strategy.